Clinical trial
A Randomized, Open-label, Two-way Crossover Study to Compare Patient Acceptability/Preference of Tiotropium Respimat® With Tiotropium Handihaler® in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT03964207 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label, Two-way Crossover Study to Compare Patient Acceptability/Preference of Tiotropium Respimat® With Tiotropium Handihaler® in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- November 25, 2019
- Completion date
- November 16, 2021
- Enrollment
- 72 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.